E.g., 19/06/2020
E.g., 19/06/2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

21 May, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect...

Information concerning 2019 dividend and the bioMérieux  General Shareholders’ Meeting 

19 May, 2020

The Board of Directors of bioMérieux met today and decided to hold the annual General Shareholders’ Meeting behind closed doors at the bioMérieux registered office on June 30, 2020. During this meeting, it will recommend reducing the 2019 dividend in order to support initiatives in the...

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch  

06 May, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS®国产微拍福利 anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV...

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization 

04 May, 2020

bioMérieux, a world leader in the field of in vitro国产微拍福利 diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Use Authorization by the U.S. Food and Drug Administration...

First-Quarter 2020 Business Review

16 April, 2020

  • bioMérieux fully mobilized against COVID-19 epidemic
  • Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter:
    • €769 million in sales
    • Up 21.5% as reported
    ...

bioMérieux’s Annual General Meeting postponed  

09 April, 2020

Due to the unprecedented circumstances linked to the COVID-19 pandemic, the Board of Directors of bioMérieux, which met today, has decided to postpone the Annual General Meeting initially scheduled on May 19, 2020 to June 30, 2020. Depending on circumstances when...

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE...

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux  

11 March, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physicians and health authorities in the fight against this emerging infectious disease...

2019 Financial Results    

26 February, 2020

  • €2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% 
  • Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sales of molecular...

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

13 January, 2020

 

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for...